Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 13, 2009-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that, after conducting an investigation, the United States Department of Justice (“DOJ”) has notified the United States District Court for the Northern District of California “of its decision not to intervene” in a lawsuit filed by a former Gilead employee under the qui tam provisions of the federal False Claims Act. The DOJ has also notified Gilead of its decision to decline to intervene in two additional False Claims Act lawsuits. If the plaintiffs in these lawsuits decide to pursue their allegations further, Gilead will defend the matters vigorously.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risks associated with being a party to any litigation matter and the inability to predict the outcome. These risks, uncertainties and other factors are described in the reports and other documents filed by Gilead with the Securities and Exchange Commission and could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements or other statements included in this press release.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Cara Miller, 650-522-1616 (Media)